Evaluating treatment patterns for metastatic urothelial carcinoma in Mexico

The ALEBRIJE study is a national-based study where we wanted to know what are the systemic therapies provided for patients with metastatic urothelial carcinoma. It’s in this scenario with a lot of challenges. We know that these patients are really a geriatric population with a lot of comorbidities and sometimes particularly in countries with low to middle-income settings, it’s difficult to access therapies. So mainly our study shows that you know many patients receive still cisplatin therapy as upfront treatment. You know platinum in general was the most common prescribed chemotherapy. It’s very unusual that they have access to novel treatment in frontline either immunotherapy alone for chemotherapy-ineligible or EV plus Pembrolizumab for platinum eligible. So I think that’s a hallmark of the study. We also know that our patients have a higher rate of disease progression on platinum therapy. It’s usually around 25 to 30 percent. Our percentage of progression was higher. Maybe it’s inadequate patient selection. Maybe it’s that the patient did not receive the dose at the time he was supposed to receive it because we have overwhelmed healthcare systems. And it’s also so unusual that they receive novel mechanisms of sanctions, such as targeted therapy with erdafitinib or antibody drug conjugates. But I think it’s very important to highlight this type of study, especially the JCOGO does a great work on that. We really need to find what are the uniqueness of urothelial carcinoma in different, you know, racial environments, geographical environments, and what are the obstacles for giving the best treatment for these populations. Thank you.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.